Aging
Navigate
Submit an Article
Research Paper|Volume 11, Issue 20|pp 8925—8936

Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention

Bangming Cao1, Fuzheng Qu1, Xianliang Liu1, Changzheng Gao2, Qiang Fu3, Chunying Jiang3, Peng Wei3,4, Qianqian Ma5
  • 1Department of Cardiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, Shandong, China
  • 2Department of Cardiology, Affiliated Hospital of Jiangnan University, Wuxi 214062, China
  • 3Department of Cardiology, Xuzhou Central Hospital, The Affiliated Hospital of Southeast University, Xuzhou 221009, Jiangsu, China
  • 4XuZhou Clinical School of Xuzhou Medical University, Xuzhou 221009, Jiangsu, China
  • 5Department of Rheumatology, Xuzhou Central Hospital, The Affiliated Hospital of Southeast University, Xuzhou 221009, Jiangsu, China
Received: July 12, 2019Accepted: September 27, 2019Published: October 30, 2019
https://doi.org/10.18632/aging.102353

Copyright © 2019 Cao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

In total, 97 acute ST-segment elevation myocardial infarction (STEMI) patients who received an emergency percutaneous coronary intervention (PCI) were enrolled and divided into a ticagrelor group and a clopidogrel group. Thrombolysis in myocardial infarction (TIMI) blood flow and the corrected TIMI frame count (CTFC) were used to assess the blood perfusion of culprit vessels. Thromboelastography (TEG) was used to evaluate the antiplatelet effect of drugs. The results showed that the incidence of TIMI grade III blood flow in the ticagrelor group was significantly higher than that in the clopidogrel group. The CTFC in the anterior descending, circumflex, and right coronary arteries was statistically significantly lower in the ticagrelor group as compared with that in the clopidogrel group. At 2 h and 7 d postdrug treatment, the adenosine diphosphate-induced platelet inhibition rate (ADP%) in the ticagrelor group increased significantly as compared with that in the clopidogrel group, and the platelet aggregation rate of the ADP pathway (MAADP) decreased significantly in the ticagrelor group versus that in the clopidogrel group. In conclusion, ticagrelor significantly improved TIMI blood flow and had a better antiplatelet effect than clopidogrel in STEMI patients undergoing an emergency PCI.